Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.48 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26194436 | 0.94 | CD274 (0.48) | CD274PDCD1VSIR | |
| SCHEMBL19939549 | 0.90 | CD274 (0.56) | CD274PDCD1VSIR | |
| SCHEMBL30668205 | 0.84 | CD274 (0.54) | CD274PDCD1VSIR | |
| SCHEMBL19939459 | 0.83 | CD274 (0.54) | CD274PDCD1VSIR | |
| SCHEMBL30395380 | 0.83 | CD274 (0.54) | CD274PDCD1VSIR | |
| SCHEMBL19897821 | 0.83 | CD274 (0.54) | CD274PDCD1VSIR | |
| SCHEMBL29615328 | 0.83 | CD274 (0.54) | CD274PDCD1VSIR | |
| SCHEMBL20522859 | 0.83 | CD274 (0.53) | CD274PDCD1VSIR | |
| SCHEMBL20523339 | 0.83 | CD274 (0.53) | CD274PDCD1VSIR | |
| SCHEMBL30254987 | 0.83 | CD274 (0.53) | CD274PDCD1VSIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059834-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10392405-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059834-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | CD274 79/4885PDCD1 382/4885VSIR 1265/4885 |
| US-20190048022-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | CD274 79/4885PDCD1 382/4885VSIR 1265/4885 |
| US-10392405-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | CD274 79/4885PDCD1 382/4885VSIR 1265/4885 |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | CD274 79/4885PDCD1 382/4885VSIR 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.